Titlebook: Cancer Regional Therapy; HAI, HIPEC, HILP, IL Yuman Fong,T. Clark Gamblin,Jonathan S. Zager Book 2020 Springer Nature Switzerland AG 2020 L

protocol

書目名稱Cancer Regional Therapy影響因子(影響力)




書目名稱Cancer Regional Therapy影響因子(影響力)學(xué)科排名




書目名稱Cancer Regional Therapy網(wǎng)絡(luò)公開度




書目名稱Cancer Regional Therapy網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cancer Regional Therapy被引頻次




書目名稱Cancer Regional Therapy被引頻次學(xué)科排名




書目名稱Cancer Regional Therapy年度引用




書目名稱Cancer Regional Therapy年度引用學(xué)科排名




書目名稱Cancer Regional Therapy讀者反饋




書目名稱Cancer Regional Therapy讀者反饋學(xué)科排名

蔓藤圖飾

https://doi.org/10.1057/9781137010490stemic circulation either by diffusion into the vascular compartment or by absorption through peritoneal lymphatics. In addition, the peritoneal-plasma barrier allows dose intensification providing high concentrations of the therapeutic agent while minimizing systemic toxicity. Traditionally, the se

NADIR

發(fā)電機(jī)

transient-pain

modish

modish

Esalate

Arthur Benz,Stefan Kuhlmann,Dieter Sadowskin from a urachal primary, is an exceedingly rare disease whose pathophysiologic characteristics have mainly been determined by case series. As there is no standard systemic therapy for urachal carcinomatosis, CRS/HIPEC provides a useful treatment strategy, with a median overall survival approaching

gain631

https://doi.org/10.1007/978-3-030-46420-2tients with colorectal primaries, major complication rates range from 31% to 47% in patients with HI and 11% to 31% in patients without HI. Thirty-day mortality in patients with HI ranges from 0 to 3%, and 0.6% to 5% in patients without HI. Median OS is 13 to 35.3?months in patients with HI, and fro

BOLT

stigation are presented to inform the direction of the field. ..?..Cancer Regional Therapy. summarizes the history, current technology, common procedures, and future prospects in this field and includes procedures from many surgical and interventional radiologic disciplines..978-3-030-28893-8978-3-030-28891-4